IQGAP1 and IGFBP2: Valuable biomarkers for determining prognosis in glioma patients

Journal of Neuropathology and Experimental Neurology

Volumn 66, Issue 5, 2007, Pages 405-417

  McDonald, Kerrie L ^a   O'Sullivan, Maree G ^b   Parkinson, Jonathon F ^a   Shaw, Janet M ^a   Payne, Cathy A ^a   Brewer, Janice M ^c   Young, Lawrence ^d   Reader, Dianne J ^c   Wheeler, Helen T ^c   Cook, Raymond J ^c   Biggs, Michael T ^c   Little, Nicholas S ^c   Teo, Charlie ^e   Stone, Glenn ^b   Robinson, Bruce G ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b CSIRO   (Australia)

^c ROYAL NORTH SHORE HOSPITAL   (Australia)

^d Dako Australian Pty Ltd Botany   (Australia)

^e Prince os Wales Private Hospital   (Australia)

Author keywords

Glioma; IGFBP2; IQGAP1; Microarray; Microvascular proliferation; Necrosis

Indexed keywords

BIOLOGICAL MARKER; IQ MOTIF CONTAINING GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN 1; SOMATOMEDIN B;

ACCURACY; ADULT; AGED; ARTICLE; ASTROCYTOMA; BIOLOGICAL ACTIVITY; CLINICAL OBSERVATION; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENE IDENTIFICATION; GLIOBLASTOMA; GLIOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MICROARRAY ANALYSIS; MULTIVARIATE ANALYSIS; OLIGODENDROGLIOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SURVIVAL TIME; TUMOR NECROSIS; TUMOR VASCULARIZATION; WORLD HEALTH ORGANIZATION;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BRAIN NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; PROGNOSIS; RAS GTPASE-ACTIVATING PROTEINS; REGRESSION ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS;

EID: 34247866468     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/nen.0b013e31804567d7     Document Type: Article

References (45)

1. Kleihues P, Cavenee WK. Pathology and Genetics of Tumours of the Nervous System: World Health Organization Classification of Tumours. Lyon: IARC, 2000
2. Hartmann C, Mueller W, von Deimling A. Pathology and molecular genetics of oligodendroglial tumors. J Mol Med 2004;82:638-55
3. Ino Y, Betensky R, Zlateseu M, et al. Molecular subtypes of anaplastic oligodendroglioma: Implications for patient management at diagnosis. Clin Cancer Res 2001;7:839-45
4. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998;90:1473-79
5. Scott JN, Rewcastle NB, Brasher PM, et al. Long-term glioblastoma multiforme survivors: A population-based study. Can J Neurol Sci 1998;25:197-201
6. Burton EC, Lamborn KR, Forsyth P, et al. Aberrant p53, mdm2, and proliferation differ in glioblastomas from long-term compared with typical survivors. Clin Cancer Res 2002;8:180-87
7. Fuller G, Mircean C, Tabus I, et al. Molecular voting for glioma classification reflecting heterogeneity in the continuum of cancer progression. Oncol Rep 2005;14:651-56
8. Godard S, Getz G, Delorenzi M, et al. Classification of human astrocytic gliomas on the basis of gene expression: A correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. Cancer Res 2003;63:6613-25
9. Hoelzinger D, Mariani L, Weis J, et al. Gene expression profile of glioblastoma multiforme invasive phenotype points to new therapeutic targets. Neoplasia 2005;7:7-16
10. Nutt C, Mani DR, Betensky RA, et al. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res 2003;63:1602-7
11. Raza S, Fuller GN, Rhee CH, et al. Identification of necrosis-associated genes in glioblastoma by cDNA microarray analysis. Clin Cancer Res 2004;10:212-21
12. Shai R, Shi T, Kremen TJ, et al. Gene expression profiling identifies molecular subtypes of gliomas. Oncogene 2003;22:4918-23
13. Tso C, Freije WA, Day A, et al. Distinct transcription profiles of primary and secondary glioblastoma subgroups. Cancer Res 2006;66:159-67
14. Freije WA, Edmundo F, Castro-Vargas F, et al. Gene expression profiling of gliomas strongly predicts survival. Cancer Res 2004;64:6503-10
15. Haven C, Howell VM, Eilers PH, et al. Gene expression of parathyroid tumors: Molecular subclassification and identification of the potential malignant phenotype. Cancer Res 2004;64:7405-11
16. Smyth GK. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004;3:Article3
17. Kiiveri HT. A Bayesian approach to variable selection when the number of variables is very large. In: Science and Statistics, Monograph, Vol 30. Hayward, CA: Institute of Mathematical Statistics, 2003
18. Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 2002;30:e36
19. Wensveen C, Kagie M, Nagelkerke N. Interobserver agreement on interpreting hand drawings of colposcopy in women with borderline cytology to predict high-grade lesions. Eur J Obstet Gynecol Reprod Biol 2006 Sep 12; [Epub ahead of print]
20. Nabeshima K, Shimao Y, Inoue T, et al. Immunohistochemical analysis of IQGAP1 expression in human colorectal carcinomas: Its overexpression in carcinomas and association with invasion fronts. Cancer Lett 2002;176:101-9
21. Sun W, Zhang K, Zhang X, et al. Identification of differentially expressed genes in human lung squamous cell carcinoma using suppression subtractive hybridization. Cancer Lett 2004:212:83-93
22. Morris LE, Bloom GS, Frierson HF, et al. Nucleotide variants within the IQGAP1 gene in diffuse-type gastric cancers. Genes Chromosomes Cancer 2005;42:280-86
23. Dong P, Nabeshima K, Nishimura N, et al. Overexpression and diffuse expression pattern of IQGAP1 at invasion fronts are independent prognostic parameters in ovarian carcinomas. Cancer Lett 2006;243:123-27
24. Balenci L, Clarke ID, Dirks PB, et al. IQGAP1 protein specifies amplifying cancer cells in glioblastoma multiforme. Cancer Res 2006;66:9074-83
25. Brown MD, Sacks DB. IQGAP1 in cellular signaling: Bridging the GAP. Trends Cell Biol 2006;16:242-49
26. Demuth T, Berens M. Molecular mechanisms of glioma cell migration and invasion. J Neurooncol 2004;70:217-28
27. Briggs MW, Li Z, Sacks DB. IQGAP1-mediated stimulation of transcriptional co-activation by β-catenin is modulated by calmodulin. J Biol Chem 2002;277:7453-65
28. Bashour AM, Fullerton AT, Hart MJ, et al. IQGAP1, a Rac- and Cdc42-binding protein, directly binds and cross-links microfilaments. J Cell Biol 1997;137:1555-66
29. Hart MJ, Callow MG, Souza B, et al. IQGAP1, a calmodulin-binding protein with a rasGAP-related domain, is a potential effector for cdc42Hs. EMBO J 1996;15:2997-3005
30. 2+/ calmodulin and Cdc42 signaling. J Biol Chem 1999;274:464-70
31. Kuroda S, Fukata M, Nakagawa M, et al. Role of IQGAP1, a target of the small GTPases Cdc42 and Rac1, in regulation of E-cadherin-mediated cell-cell adhesion. Science 1998;281:832-35
32. Lehtonen S, Ryan JJ, Kudlicka K, et al. Cell junction-associated proteins IQGAP1, MAGI-2, CASK, spectrins, and α-actinin are components of the nephrin multiprotein complex. Proc Natl Acad Sci U S A 2005;102:9814-19
33. Bourguignon LY, Gilad E, Rothman K, et al. Hyaluronan-CD44 interaction with IQGAP1 promotes Cdc42 and ERK signaling, leading to actin binding, Elk-1/estrogen receptor transcriptional activation, and ovarian cancer progression. J Biol Chem 2005;280:11961-72
34. Fan X, Salford LG, Widegren B, et al. Glioma stem cells: Evidence and limitation. Semin Cancer Biol 2006 May 4; [Epub ahead of print]
35. Zhou Y, Hess KR, Liu L, et al. Modeling prognosis for patients with malignant astrocytic gliomas: Quantifying the expression of multiple genetic markers and clinical variables. Clin Neuro-Oncol 2005;7:485-94
36. Zhang W, Wang H, Song SW, et al. Insulin-like growth factor binding protein 2: Gene expression microarrays and the hypothesis-generation paradigm. Brain Pathol 2002;12:87-94
37. Wang H, Wang H, Shen W, et al. Insulin-like growth factor binding protein 2 enhances glioblastoma invasion by activating invasion-enhancing genes. Cancer Res 2003;63:4315-21
38. Houillier C, Lejeune J, Benouaich-Amiel A, et al. Prognostic impact of molecular markers in a series of 220 primary glioblastomas. Cancer 2006;106:2218-23
39. Hill C, Hunter SB, Brat DJ. Genetic markers in glioblastoma: Prognostic significance and future therapeutic implications. Adv Anat Pathol 2003;10:212-17
40. Dong S, Nutt CL, Betensky RA, et al. Histology-based expression profiling yields novel prognostic markers in human glioblastoma. J Neuropath Exp Neurol 2005;64:948-55
41. Elmlinger M, Deininger MH, Schuett BS, et al. In vivo expression of insulin-like growth factor-binding protein-2 in human gliomas increases with the tumor grade. Endocrinology 2001;142:1652-58
42. Brat D, Castellano-Sanchez AA, Hunter SB, et al. Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. Cancer Res 2004;64:920-27
43. Zagzag D, Lukyanov Y, Lan L, et al. Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: Implications for angiogenesis and glioma cell invasion. Lab Invest 2006;86:1221-32
44. Wang G, Hu L, Fuller GN, et al. An interaction between insulin-like growth factor binding protein 2 (IGFBP2) and integrin α5 is essential for IGFBP2-induced cell mobility. J Biol Chem 2006;281:14085-91
45. Iwaki T, Yamamoto K, Matsuura T, et al. Alteration of integrins under hypoxic stress in early placenta and choriocarcinoma cell line BeWo. Gynecol Obstet Invest 2004;57:196-203